Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

BMC Psychiatry · 2025 · PMC12581406 · PMID 41184790

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

At the primary endpoint, sulforaphane at lower doses (66 and ~ 100 μmol/day) did not show a statistically significant improvement in PANSS total score, but with the highest dose (136 μmol/day) a trend toward improvement was observed that did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.